BCIQ Profiles

Company Profile ReportTarget Profile Report

Otsuka's guadecitabine misses in Phase III for first-line AML

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) and its Astex Pharmaceuticals Inc. subsidiary said first-line treatment with guadecitabine (formerly SGI-110) missed

Read the full 209 word article

How to gain access

Continue reading with a
two-week free trial.